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OBJECTIVE—Chronic low-grade activation of the immune sys-
tem (CLAIS) predicts type 2 diabetes via a decrease in insulin
sensitivity. Our study investigated potential relationships be-
tween nuclear factor-B (NF-B) and c-Jun NH2-terminal kinase
(JNK) pathways—two pathways proposed as the link between
CLAIS and insulin resistance.
RESEARCH DESIGN AND METHODS—Adiposity (dual-
energy X-ray absorptiometry), waist-to-hip ratio (WHR), and
insulin sensitivity (M, hyperinsulinemic-euglycemic clamp) were
measured in 22 healthy nondiabetic volunteers (aged 29  11
years, body fat 28  11%). NF-B activity (DNA-binding assay)
and JNK1/2 activity (phosphorylated JNK) were assessed in
biopsies of the vastus lateralis muscle and subcutaneous adipose
tissue and in peripheral blood mononuclear cell (PBMC) lysates.
RESULTS—NF-B activities in PBMCs and muscle were posi-
tively associated with WHR after adjustment for age, sex, and
percent body fat (both P  0.05). NF-B activity in PBMCs was
inversely associated with M after adjustment for age, sex, per-
cent body fat, and WHR (P  0.02) and explained 16% of the
variance of M. There were no signiﬁcant relationships between
NF-B activity and M in muscle or adipose tissue (both NS).
Adipose-derived JNK1/2 activity was not associated with obesity
(all P  0.1), although it was inversely related to M (r  0.54,
P  0.05) and explained 29% of its variance. When both NF-B
and JNK1/2 were examined statistically, only JNK1/2 activity in
adipose tissue was a signiﬁcant determinant of insulin resistance
(P  0.02).
CONCLUSIONS—JNK1/2 activity in adipose tissue but not
NF-B activity in PBMCs is an independent determinant of
insulin resistance in healthy individuals. Diabetes 58:1259–
1265, 2009
C
hronic low-grade activation of the immune
system (CLAIS) (i.e., increased plasma inﬂam-
matory markers without overt signs of inﬂam-
mation) is suggested to play an etiological role
in the development of type 2 diabetes. Support for this
hypothesis is derived from cross-sectional (1–3) and pro-
spective (4–7) studies demonstrating associations be-
tween elevation in markers of inﬂammation and obesity,
insulin resistance, and/or type 2 diabetes. We provided the
ﬁrst prospective evidence in healthy, normal glucose tol-
erant individuals that CLAIS may contribute to the devel-
opment of type 2 diabetes by causing a decline in insulin
sensitivity (7), which has since been conﬁrmed by two
other studies (6,8). However, the exact mechanisms
whereby activation of the immune system could contrib-
ute to insulin resistance are not completely understood.
The nuclear factor-B (NF-B)/inhibitor of B( I B) ki-
nase (IKK)  (7) and c-Jun NH2-terminal kinase (JNK)
pathways (9) have been proposed as two possible links
between activation of the immune system and the devel-
opment of insulin resistance and type 2 diabetes.
NF-B is a sequence-speciﬁc transcription factor most
commonly found as a heterodimer of p65 (RelA) and p50,
which induces the transcription of inﬂammatory genes
(10,11) and other genes that may alter insulin action (12).
NF-B is maintained in the cytoplasm through interaction
with inhibitory proteins, the IBs, which are rapidly de-
graded upon phosphorylation by IKK. The inhibitory effect
of NF-B on insulin action is thought to be mediated by
phosphorylation of serine residues of insulin receptor
substrate (12). Recently, it has been shown that mice
lacking IKK in peripheral blood mononuclear cells
(PBMCs) are unable to translocate NF-B, which protected
them from systemic insulin resistance (13). This ﬁnding
suggested for the ﬁrst time that peripheral blood mono-
cytes might be more important in the development of
insulin resistance than skeletal muscle or adipose tissue.
Jun NH2-terminal kinases belong to a mitogen-activated
protein kinase family that controls cell development and
function by regulation of transcription by phosphorylating
protein 1 complex proteins including c-Jun and JunB.
There are three isoforms, with JNK1 and JNK2 being
present in most cells and tissues (14). In particular, JNK1
appears to be the predominant isoform present in muscle,
liver, and adipose tissues. JNK1 has been shown to inter-
fere with insulin action in cultured cells (15); JNK activity
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DIABETES, VOL. 58, JUNE 2009 1259is abnormally elevated in obesity, and an absence of JNK1
results in decreased adiposity, improved insulin sensitiv-
ity, and enhanced insulin receptor signaling in two differ-
ent mouse models of obesity (9). Therefore, JNK1 is now
considered an important player in the modulation of
insulin action and a critical component of the pathogene-
sis of obesity, insulin resistance, and type 2 diabetes (9).
There is a paucity of data exploring the hypothesis that
either or both of these pathways play a role in CLAIS-
induced insulin resistance in humans. In particular, no
study investigated these pathways in healthy individuals
before they develop diabetes, which is essential with
respect to etiology of insulin resistance. An association
between NF-B activation and glucose metabolism has
been suggested in patients with type 2 diabetes, in whom
there was a 60% reduction in the protein levels of IKK and
a parallel elevation of NF-B activity in skeletal muscle
biopsies, which correlated with insulin resistance (16). In
another study in insulin-resistant women with polycystic
ovary syndrome (a condition also associated with CLAIS)
NF-B expression correlated with 2-h glucose levels (17).
Furthermore, increased NF-B activity in mononuclear
cells has been shown in patients with type 2 diabetes
(18,19) as well as in obese individuals (20). However, none
of these studies investigated NF-B activity in relation to
direct assessment of insulin sensitivity, as measured by
the hyperinsulinemic-euglycemic clamp. With regard to
JNK1 activity, we have also previously shown that obese
insulin-resistant humans (insulin sensitivity assessed by
homeostasis model assessment [HOMA]) have increased
JNK phosphorylation in skeletal muscle (21). Only one
other study demonstrated that JNK1 activity in skeletal
muscle was increased in obesity and type 2 diabetes and
was an independent determinant of insulin resistance as
measured by euglycemic clamp (22), but in that study
adipose tissue and PBMCs were not examined.
Thus far, no studies have investigated the relative con-
tribution of NF-B and JNK pathways to development of
insulin resistance in humans. Because it is likely that the
relationship between CLAIS and insulin resistance can be
initiated and perpetuated systemically by cross talk among
insulin-sensitive tissues, i.e., adipose tissue, skeletal mus-
cle, liver, and circulating immune cells, we sought to
investigate these pathways in relation to insulin resistance
in skeletal muscle, adipose tissue, and PBMCs. Therefore,
we hypothesized that sustained activation of NF-B and/or
JNK1 in PBMCs and/or insulin-sensitive tissues such as
skeletal muscle and subcutaneous adipose tissue contrib-
utes to development of insulin resistance in nondiabetic
and otherwise healthy individuals.
RESEARCH DESIGN AND METHODS
Twenty-two volunteers (10 women) aged between 18 and 50 years underwent
a rigorous protocol using standard measures of obesity and insulin resistance.
Speciﬁcally, participants were nondiabetic (normal glucose tolerance or
impaired glucose tolerance) according to an oral glucose tolerance test
(OGTT) (World Health Organization 1999 criteria), nonsmokers at the time of
the study, and healthy according to a detailed physical examination and
routine blood analyses. No participants had clinical or laboratory signs of
acute or chronic infection or took any medication or used illicit drugs at the
time of the study. The protocol was approved by the Alfred Hospital Ethics
Committee and complied with the Declaration of Helsinki 2004. All subjects
provided written informed consent before participation. All participants were
characterized for plasma inﬂammation markers, body composition, glucose
tolerance, insulin action, and NF-B and JNK1 activity in PBMCs and muscle
and adipose tissue (Table 1).
All subjects underwent medical screening, which included history, physical
examination, and basic laboratory tests (including fasting plasma lipid levels,
liver function tests, urea, creatinine, and electrolyte levels, urinary illicit drug
screening, an anthropometric assessment, an OGTT, and a hyperinsulinemic-
euglycemic glucose clamp. Before metabolic testing, participants were asked
to abstain from strenuous exercise and caffeine for 3 days. All of the metabolic
testing was performed after a 12-h overnight fast.
Anthropometric measurements. Body composition was estimated by total-
body dual-energy X-ray absorptiometry (DPX-L; Lunar Radiation, Madison,
WI) with calculations of percent body fat, fat mass, and fat-free mass as
described previously (11). Waist and hip circumferences were measured and
waist-to-hip ratio (WHR) was calculated as an index of body fat distribution.
Metabolic studies. A 2-h 75-g OGTT was performed after a 12-h overnight
fast, and glucose tolerance status was determined by World Health Organiza-
tion 1999 criteria. Plasma glucose concentrations were determined by the
glucose oxidase method (ELM 105; Radiometer, Copenhagen, Denmark).
Insulin action was assessed at physiological insulin concentrations during
a hyperinsulinemic-euglycemic clamp. In brief, after an overnight fast, a
primed continuous intravenous insulin infusion (9 mU/kg) was administered
for 120 min at a constant rate of 40 mU/m
2 body surface area per minute (M).
Plasma glucose was measured every 5 min during the clamp, and the variable
infusion rate of glucose was adjusted to maintain blood glucose at a constant
value of 5 mmol/l. This infusion achieved steady-state plasma insulin concen-
trations. The rate of total insulin-stimulated glucose disposal (M) was calcu-
lated for the last 40 min of the insulin infusions. Blood samples for analysis of
inﬂammation markers were drawn before the start of the glucose clamp.
Muscle and adipose tissue biopsies. Biopsies of subcutaneous adipose and
vastus lateralis muscle were performed on a separate day using standard
aseptic technique and local anesthesia. In brief, before a percutaneous muscle
biopsy of the vastus lateralis muscle, a scalpel blade was used to make a 7-mm
skin incision and to cut the fascia. A side-cutting muscle biopsy needle was
passed through the incision to obtain 100 mg of muscle tissue. Adipose
tissue was obtained by needle biopsy from the abdominal area, 1–2 cm
superior to McBurney’s point. After making an 5-mm skin incision, the
needle biopsy was performed using a 50-ml plastic syringe attached to a
13-gauge aspiration needle. The muscle and adipose tissues were immediately
placed in liquid nitrogen and then stored at 80°C.
Blood sample analysis. Blood samples were drawn using standard phlebot-
omy techniques into sodium citrate Vacutainers for measurement of inﬂam-
matory markers. The tubes were centrifuged immediately (1,500g, 15 min,
4°C), and the plasma was stored at 80°C until analyses were performed.
Monocyte chemoattractant protein-1 (MCP-1) was measured using a Beadlyte
plex kit (Upstate Cell Signaling Solutions, Charlottesville, VA). Multiplexed
assays were run according to the manufacturer’s instructions on a Luminex
100 Bioplex machine using Luminex Pro software version 1.7 (Bio-Rad,
Atherton, CA). Plasma high-sensitivity C-reactive protein (hsCRP) was mea-
sured by an immunoturbidimetric assay. Hepatic enzymes, alanine amino-
transferase (ALT) and 	-glutamyltranspeptidase (GGT), were measured by
NADH (without P-5
-P) and L-	-glutamyl-3-carboxy-4-nitroanilide substrates,
respectively. hsCRP and hepatic enzymes (ALT and GGT) were measured by
Alfred Hospital Pathology Services using the Architect system (Abbott Diag-
nostics, Abbott Park, IL).
NF-B activity measurements. PBMCs were isolated from whole blood
using Ficoll-Paque Plus density centrifugation (Amersham Biosciences, Upp-
TABLE 1
Anthropometric and metabolic parameters of the study
population
All Women Men
n 22 10 12
Age (years) 29  11 31  12 27  10
Weight (kg) 75  11 71  12 79  9
BMI (kg/m
2) 25  42 5  42 6  4
Waist circumference (cm) 84  10 82  11 85  10
WHR 0.85  0.08 0.82  0.07 0.88  0.08
Body fat (%) 28  11 36  72 2  9*
Fasting glucose (mmol/l) 4.5  0.5 4.3  0.4 4.7  0.5
2-h glucose (mmol/l) 4.6  1.3 4.7  1.6 4.6  1.1
M (mg kg
1  min
1) 10.3  4.4 10.7  5.3 9.9  3.8
White blood cells (10
9/l) 5.8  1.0 5.8  1.1 5.9  1.0
hsCRP (mg/l) 1.1  1.1 1.4  1.2 0.9  0.9
MCP-1 (ng/ml) 15.3  17.5 10.7  11.7 19.1  20.0
ALT (units/l) 17  91 3  42 0  10
GGT (units/l) 21  14 16  52 6  18
Data are means  SD. *P  0.05 male vs. female subjects.
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stored at 80°C.
Nuclear extraction from PBMCs and adipose and skeletal muscle tissue
was performed. Brieﬂy, muscle and adipose tissue biopsy samples were
homogenized in a 1:5 w/v ice-cold homogenization buffer (50 mmol/l Tris-HCl,
pH 7.8, 10 mmol/l EDTA, pH 8.0, 100 mmol/l NaF, 2 mmol/l Na3VO4, 1 mmol/l
sodium pyrophosphate, 250 mol/l phenylmethylsulfonyl ﬂuoride, 10 g/ml
aprotinin, and 10 g/ml leupeptin) with a hand-held homogenizer (Polytron-
Aggregate; Kinematica, Switzerland). Samples were then rotated for 30 min,
end-over-end, at 4°C, before being centrifuged (14,000g, 30 min, 4°C) to isolate
the nuclear pellet. The nuclear pellet was then resuspended in 500 l buffer A
(10 mmol/l HEPES, pH 7.9, 10 mmol/l KCI, 0.1 mmol/l EDTA, 0.1 mmol/l EGTA,
and 0.7% v/v IGEPAL), vortexed and centrifuged (7,000g, 1 min, room
temperature), and then resuspended in 500 l buffer B (10 mmol/l HEPES, pH
7.9, 10 mmol/l KCI, 0.1 mmol/l EDTA, and 0.1 mmol/l EGTA). Supernatant was
removed, and the pellet was resuspended in 150 l buffer C (20 mmol/l HEPES,
pH 7.9, 400 mmol/l NaCl, 1 mmol/l EDTA, and 1 mmol/l EGTA), incubated on ice
for 20 min, and then centrifuged (10,000g, 30 min, room temperature). The
resulting supernatant was used in the NF-B DNA-binding assay.
PBMC samples were washed in excess PBS and centrifuged (400g, 5 min,
4°C), to remove residual FBS and DMSO. The supernatant was discarded, and
the pellets were resuspended in 100 l triple detergent buffer (50 mmol/l
Tris-HCl, pH 8.0, 150 mmol/l NaCl, 0.02% NaN3, 0.1% SDS, 100 g/ml phenyl-
methylsulfonyl ﬂuoride, 1 g/ml aprotinin, 1% Nonidet P-40, and 0.5% sodium
deoxycholate, in Milli-Q H2O). These were then sonicated for 1 min and
centrifuged (400g, 3 min, 4°C). The resulting supernatant was used in the
NF-B assay. The protein concentration of all protein isolates was determined
using the bicinchoninic acid protein assay (Pierce, Rockford, IL), performed
according to the manufacturer’s instructions.
The TransAM NFB DNA-binding activity assay (Active Motif, Carlsbad,
CA) was used to detect and quantify NF-B transcription factor activation,
speciﬁcally of the p65 subunit. Nuclear extracts obtained from muscle (1 g
protein/well) and adipose tissue (5 g protein/well) biopsies and PBMC (30 g
protein/well) samples were analyzed for their binding capacity to an NF-B
consensus sequence in labeled DNA in a 96-well plate format. The assays were
performed according to the manufacturer’s instructions, and absorbance was
measured on a Victor3V Multilabel plate reader (PerkinElmer, Wellesley, MA).
Results are expressed as nanograms of p65 activity per microgram of protein.
JNK1/2 activity measurements. Phosphorylation of JNK ([Thr
183/Tyr
185]/
total JNK) was used as a surrogate for JNK1/2 activity as described previously
(21). PBMC, subcutaneous adipose tissue, and skeletal muscle samples were
homogenized, and protein concentrations were determined. Total protein (40
g) was separated by SDS-PAGE and blotted onto a polyvinylidene ﬂuoride
membrane. Blots were performed for phosphorylated JNK (1:1,000) and total
JNK (1:1,000) using antibodies from Cell Signaling Technologies. Bands were
visualized using a Bio-Rad anti-rabbit IgG horseradish peroxidase (1:4,000)
conjugated antibody and ECL solution (Sigma) and developed on ﬁlm. Bands
were quantiﬁed using Quantity One Imaging software. JNK1/2 activity in
muscle and adipose tissue was available for only 18 individuals because
insufﬁcient tissue was available for analyses.
Real-time analysis (RT-PCR). Gene expression of the p65 subunit of NF-B
and IB in PBMCs was assessed by real-time quantitative RT-PCR, per-
formed using the TaqMan system based on real-time detection of accumulated
ﬂuorescence (ABI Prism 7700 sequence detection system; PE Biosystems,
Foster City, CA) as described previously (23). Brieﬂy, 4 g total RNA was
isolated from PBMCs with TRIzol according to the manufacturer’s instruc-
tions (Gibco BRL, Grand Island, NY). The resulting RNA was used to
synthesize cDNA with a Superscript First Strand synthesis system (Gibco
BRL). To control for variation in the amount of DNA available for PCR in the
different samples, gene expression was normalized simultaneously (by multi-
plexing) in relation to the expression of the housekeeping gene 18S rRNA (18S
rRNA TaqMan Control Reagent kit) as an endogenous control. Primers and
TaqMan probes for the proteins described above were constructed with the
help of Primer Express (PerkinElmer) (for sequences, see Table 2) and
ﬂuorescence for each cycle was quantitatively analyzed by an ABI Prism 7700
sequence detection system. Results are expressed as arbitrary units, related to
minor groove binding (MGB) probe sample ﬂuorescence, corrected to endog-
enous 18S expression.
Statistical analysis. Statistical analyses were performed using SAS Jump
statistics software (SAS Institute, Cary, NC). Results are given as means  SD
(unless indicated otherwise). The values for inﬂammatory markers and M
were logarithmically transformed before analysis to approximate normal
distributions.
The relationships between inﬂammatory markers, NF-B, JNK1/2, and
anthropometric and metabolic variables were examined by calculating Pear-
son correlation coefﬁcients, and P values were corrected for multiple com-
parisons (Benjamini-Hochberg procedure). Multiple linear regression models
and partial correlations were used to examine the relationships after adjust-
ment for covariates. Stepwise regression was used to determine a relative
contribution of each of the variables to the model. Differences between men
and women were assessed by unpaired Student’s t test. Statistical signiﬁcance
was assumed when P  0.05.
Our correlation tests are sufﬁciently sensitive at 0.05 with a power of 1 
0.80 for two-sided correlations at r  0.53 and for one-sided correlations at
r  0.48 (n  22, degrees of freedom  20). Because inﬂammation markers are
known to be positively associated with obesity and negatively with insulin
sensitivity, the one-sided calculation is most relevant to the current analyses. Post
hoc statistical power calculations for the multiple regression models of our main
ﬁndings, which all had R
2 0.6, give power estimates greater than 0.90 for up to
ﬁve independent variables in the model at 0.05.
RESULTS
The anthropometric and metabolic characteristics of the
whole study population are summarized in Table 1. All
subjects were deemed healthy according to their physical
examination, were normotensive with normal lipid proﬁle,
full blood count, plasma CRP levels, liver function tests
(Table 1), and renal function (estimated glomerular ﬁltra-
tion rate 60 ml/min per m
2), and therefore subclinical
inﬂammation was ruled out. Women had higher percent
body fat and HDL cholesterol levels, but there were no
other sex differences seen among any of the other anthro-
pometric and metabolic variables.
Relationship between NF-B and JNK1/2 activity.
NF-B activity in PBMCs was positively associated with
NF-B activity in the skeletal muscle (r  0.68, P  0.0004)
but not in adipose tissue (r  0.17, P  0.4). JNK1/2
activity in PBMCs was not related to JNK1/2 activity in
skeletal muscle (r  0.14, P  0.6) or subcutaneous
adipose tissue (r  0.34, P  0.2). In addition, no
relationship between JNK1/2 activity and NF-B activity
was identiﬁed in any of the tissues studied (all P  0.2).
Relationship of NF-B and JNK1/2 to inﬂammation
markers. White blood cell count (r  0.39, P  0.05) and
plasma levels of MCP-1 (r  0.63, P  0.05) were each
associated with NF-B activity in PBMCs but not with
NF-B activity in the skeletal muscle or subcutaneous
adipose tissue (Table 3). Plasma hsCRP (Table 3) was not
related to NF-B activity in any of the tissues investigated
and did not correlate with insulin sensitivity (r  0.20, P 
0.4). JNK1/2 activity was not associated with any of these
markers of inﬂammation (P  0.1).
Relationship of NF-B and JNK1/2 to obesity. NF-B
activity in either PBMCs or skeletal muscle was not
associated with an overall measure of obesity, percent
body fat (Table 3, Fig. 1). NF-B activity in subcutaneous
adipose tissue also was not related to any of the anthro-
pometric variables. Furthermore, the gene expression of
IB and NF-B (p65) in PBMC did not correlate with any
TABLE 2
Real-time RT-PCR probes and primers used for ampliﬁcation of NF-B p65 and IB in PBMCs
Target Probe Forward primer 5
–3
 Reverse primer 5
–3

NF-B p65 6-FAM AGCTCAAGATCTGCCG CTCATCCCATCTTTGACAATCGT TGCACCTTGTCACACAGTAGGAA
IB 6-FAM CTTCCAGAACAACCTGC AGGGAGACCTGGCCTTCCT TTCTGGCTGGTTGGTGATCA
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activity in PBMCs (data not shown). However, we found
that NF-B activity in both PBMCs and skeletal muscle
was positively associated with WHR (r  0.48, P  0.02;
r  0.68, P  0.003) (Table 3, Fig. 1) before and after
adjustment for age and sex (both P  0.05). This associa-
tion persisted after additional adjustment for percent body
fat (both P  0.05). Tissue JNK1/2 activity was not related
to any measures of obesity (both P  0.1) (Table 3).
Relationship of NF-B and JNK1/2 to insulin sensi-
tivity. NF-B activity in PBMCs was inversely associated
with insulin sensitivity before (r  0.46, P  0.03) (Table
3) and after adjustment for age, sex, percent body fat, and
WHR (P  0.02). In stepwise regression, elevated NF-B
activity in PBMCs explained 16% of the variance in the
model after adjustment for the variables stated above.
NF-B activity in skeletal muscle and adipose tissue were
not associated with insulin sensitivity (both P  0.1).
JNK1/2 activity in the adipose tissue was related to
insulin sensitivity (r  0.54, P  0.05) (Fig. 2) before and
after adjustment for age, sex, percent body fat, and WHR
(P  0.04). In stepwise regression with age, sex, percent
body fat, and WHR, JNK1/2 activity in adipose tissue
explained the 29% variance in insulin sensitivity (P  0.02).
TABLE 3
Pearson correlation coefﬁcients between NF-B and JNK1/2 activity in PBMCs and muscle and adipose tissue with anthropometric
and metabolic variables
NF-B JNK1/2
PBMCs Muscle Adipose tissue PBMCs Muscle Adipose tissue
Age 0.16 0.11 0.35 0.009 0.09 0.01
% body fat 0.20 0.09 0.21 0.14 0.12 0.07
Waist 0.17 0.29 0.08 0.06 0.29 0.32
WHR 0.48* 0.68* 0.03 0.14 0.40 0.04
M 0.46* 0.29 0.15 0.08 0.23 0.54*
WBC 0.39 0.20 0.18 0.13 0.20 0.04
hsCRP 0.11 0.13 0.03 0.41 0.39 0.002
MCP-1 0.63* 0.36 0.21 0.02 0.03 0.21
*P  0.05. WBC, white blood cell count.
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FIG. 1. NF-B p65 activity in PBMCs and central obesity, insulin sensitivity, and JNK1 activity in subcutaneous adipose tissue and insulin
sensitivity. A: NF-B p65 activity in PBMCs and WHR. B: NF-B p65 activity in PBMCs and total body fat. C: NF-B p65 activity in PBMCs and
M. D: JNK1/2 activity and insulin sensitivity (M).
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PBMCs were entered in the same model, only JNK1/2
activity in adipose tissue remained a signiﬁcant determi-
nant of insulin sensitivity, explaining 29% (P  0.02),
whereas percent body fat contributed 21% (P  0.02) and
sex 10% (P  0.07). When forced into this model, NF-B
activity in PBMCs explained only 4% of the variance in
insulin sensitivity (P  0.1). JNK1/2 activity in PBMCs and
muscle was not associated with any measures of obesity
or glucose metabolism (all P  0.2). Exclusion of the two
subjects with impaired glucose metabolism (one with
impaired glucose tolerance and one with impaired fasting
glucose) did not signiﬁcantly alter the correlations
presented.
DISCUSSION
In the present study, we showed for the ﬁrst time that,
among healthy, nondiabetic individuals, both NF-B activ-
ity in PBMCs and JNK1/2 activity in subcutaneous adipose
tissue were important determinants of insulin resistance
and explained 16 and 29%, respectively, of its variance
after adjustment for appropriate covariates. Moreover,
NF-B activity in both PBMCs and skeletal muscle was
also associated with central obesity.
The cross-sectional relationships between NF-B activ-
ity in PBMCs and adiposity were consistent with previous
ﬁndings in obese patients in whom NF-B activity in
PBMCs was elevated (20,24) and correlated with BMI
(20,25). We added to the current evidence by showing this
relationship across a wide range of adiposity. We also
provided more precise measures of overall adiposity,
speciﬁcally percent body fat by dual-energy X-ray absorp-
tiometry as opposed to BMI, but, interestingly, our study
showed that NF-B activity in PBMCs was speciﬁcally
associated with central obesity but not overall adiposity
(measured as total percent body fat or BMI), perhaps
because we have studied participants with a wide range of
adiposity as opposed to only morbidly obese patients. In
the above-mentioned studies (20,24), the relationship be-
tween central adiposity and NF-B activity was not inves-
tigated. It is well established that central adiposity is a
stronger predictor than overall adiposity of insulin resis-
tance and progression to type 2 diabetes than overall
adiposity and is likely to be responsible for the proinﬂam-
matory phenotype seen in these conditions (26–31). Thus,
our additional ﬁndings showed for the ﬁrst time a relation-
ship between NF-B activity in skeletal muscle and central
obesity, suggesting that activation of the NF-B/IB path-
way in muscle may contribute to a local inﬂammatory
environment due to lipid accumulation and contributing to
insulin resistance.
In accordance with two other studies (20,24), we also
found a relationship between increased NF-B activity in
PBMCs and insulin resistance. In contrast to these studies,
which used a calculated HOMA as a proxy for insulin
resistance, we examined insulin resistance directly using
the standard hyperinsulinemic-euglycemic clamp. More-
over, we showed that the relationship between NF-B
activity in PBMCs and insulin resistance is independent of
the degree of obesity and explained 16% of variance in
insulin resistance after adjustment for age, sex, percent
body fat, and WHR. Although previous studies have shown
that NF-B activation in skeletal muscle is related to
insulin resistance in obese humans (20,24), this was not
seen in our study in nondiabetic healthy individuals. Our
data are consistent with rodent studies in which overex-
pression of the p65 subunit of NF-B in skeletal muscle
had no effect on insulin resistance as measured by glucose
clamp (32). In our study, we also found no relationship
between activation of NF-B in adipose tissue and any of
the anthropometric or metabolic parameters. Animal mod-
els of type 2 diabetes have demonstrated an association
between insulin resistance and elevated levels of the
activator of NF-B, IKK, at the gene level, in perigonadal
but not in mesenteric adipose tissue (33). Gene levels of
the inhibitor of NF-B( I B) have also been associated
with central adiposity in obese elderly women (34). Both
of these studies (33,34), however, examined only gene
expression as opposed to activity. The absence of an
association between NF-B activity in adipose tissue and
anthropometric or metabolic parameters in the present
study could also be due to differences in the populations
examined. Both of the previously reported studies de-
scribed the relationship in obese and insulin-resistant
animals/populations (33,34), whereas our study was con-
ducted in a healthy population.
Interestingly, NF-B activity in PBMCs was associated
with circulating MCP-1 levels but not with CRP. MCP-1 is
one of the many downstream cytokine targets of the key
proinﬂammatory transcription factor, NF-B. MCP-1 is
known to recruit white blood cells to the site of inﬂam-
mation and therefore may be considered an important
driver and perpetuator of NF-B activation and inﬂamma-
tion (35). NF-B activity in PBMCs and adipose tissue have
been shown previously to correlate with the gene (20,34)
and protein (20) expression of interleukin-6, macrophage
inhibitory factor, and hsCRP in obese individuals. In our
study, however, plasma levels of CRP were not associated
with either NF-B activity or insulin sensitivity probably
because of the low plasma levels of CRP (all values within
normal range) in our healthy nondiabetic population.
Therefore, NF-B may be a more sensitive early marker of
inﬂammation than CRP in healthy individuals. We have made
the novel observation that NF-B activity in PBMCs is an
important determinant of both central adiposity and insulin
resistance. Interestingly, Arkan et al. (13) demonstrated that
mice lacking IKK in PBMCs, which makes them unable to
activate the NF-B/IB pathway, are protected from systemic
insulin resistance. Our data demonstrated this relationship
for the ﬁrst time in humans.
To date, JNK1/2 activity has only been associated with
obesity in animal models of obesity and diabetes (9). In
this study, we showed that JNK1/2 activity in PBMCs,
skeletal muscle, and subcutaneous adipose tissue was not
associated with any measure of obesity in humans. Impor-
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FIG. 2. Representative immunoblots of human adipose tissue (n  6)
probed for total JNK (tJNK) and phosphorylated JNK (pJNK,
Thr
183/Tyr
185).
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activity in subcutaneous adipose tissue was associated
with insulin resistance, independently of age, sex, percent
body fat, and WHR and explained 29% of the variance in
insulin resistance after adjustment for these covariates. In
this study, we have made the novel observation that when
both NF-B activity in PBMCs and JNK1/2 activity in
subcutaneous adipose tissue are included in this model,
only JNK1/2 activity was a signiﬁcant determinant of
insulin resistance, suggesting not only that these pathways
are codependent but also that JNK1/2 activity is an inde-
pendent and therefore potentially more important deter-
minant of insulin resistance in nondiabetic, otherwise
healthy individuals. JNK activity in skeletal muscle has
been shown to be associated with insulin resistance in
obese and diabetic subjects (22). We have also shown
previously that obese insulin-resistant humans (insulin
sensitivity assessed by HOMA) have increased JNK1/2
phosphorylation in skeletal muscle (21). In our present
study, however, we did not see a relationship between
JNK1/2 activity in skeletal muscle and insulin resistance,
most likely because of our different study population, i.e.,
healthy nondiabetic individuals versus obese, type 2 dia-
betic subjects. Adipose tissue JNK activity was not exam-
ined in either of these previous studies (21,22), so we
cannot compare our results in this regard. It could be
hypothesized that different inﬂammatory pathways may be
important in the initiation of insulin resistance as opposed
to when diabetes has already developed. In our study,
tissue JNK1/2 activity was not associated with circulating
inﬂammatory makers, suggesting that tissue-speciﬁc in-
ﬂammation and activation of JNK are enough to cause
insulin resistance.
Our study has several limitations. First, because of the
cross-sectional nature of the study, we cannot delineate
the cause and effect relationships between JNK and NF-B
activity and insulin resistance. Second, the sample size is
small, and, hence, the results should be interpreted with
caution. However, the strength of the correlations and
their robustness in various adjusted models attests to the
validity of our ﬁndings. Third, standard imaging methods
such as computed tomography or magnetic resonance
imaging would have provided a better assessment of
central adiposity than waist circumference.
In conclusion, we have demonstrated that elevated
NF-B activity in PBMCs and JNK1/2 activity in subcuta-
neous adipose tissue are both important determinants of
insulin resistance in a healthy nondiabetic population.
Moreover, we show that JNK1/2 activity in adipose tissue
but not NF-B activity in PBMC is an independent deter-
minant of insulin resistance in this population. Further
investigation is warranted to determine the mechanisms
by which changes in NF-B and JNK1/2 activity contribute
to the development of type 2 diabetes in humans.
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